<?xml version="1.0" encoding="UTF-8"?>
<p>Other medication should be added depending on the clinical and laboratory signs: for the ′ground glass′ image on imagistics, which signals presence of intra-alveolar- and intravascular emboli, especially when D-dimer is elevated: administration of anticoagulant, heparin or fractionated heparin; for signs of porphyria (spontaneous ecchymosis which do not change color) - chloroquine, amodiaquine, curcumin; for tachycardic, tachyarrhythmic patients amiodarone 400 mg qd for a maximum 7 days; for all patients and especially with high cholesterol, simvastatin for asthma patients, Montelukast and/or fexofenadine or other lipophilic antihistaminic and anti- inflammatory, preferably curcumin; for anti-inflammatory, analgesic actions - PPAR-α/γ agonists fenofibrate/pioglitasone or ABDH6 inhibitors KT185 and KT203 (which decrease macrophage activation and pain-inflicting CCXl-2 with allodynia); rabeprazole for preventing gastritis and for possible antiviral effects; methylprednisolone was shown to be of benefit in COVID-19 (
 <xref rid="b4-ijmm-46-02-0489" ref-type="bibr">4</xref>), and even with associated immune depression favoring viral replication, it can be considered for short-term in severely ill.
</p>
